People may not have to microdose psychedelics to feel their wellbeing benefits – they just have to believe they’ve microdosed them, according to researchers from Imperial College London.
Migraine sufferers who use cannabis for pain relief may be at higher odds of developing a “rebound” headache, according to new research from Stanford University.
Hemp crops may have more in common with recreational, “drug-type” varieties of cannabis than previously thought, according to new research from the University of Minnesota.
Alisia Ratliff, CEO of Victus Capital Ventures, explores the world of cannabis separation techniques – the good, the bad, and the expensive.
The biotech and life sciences company Mydecine Innovations Group recently announced it had completed its first commercial export of legal psychedelic psilocybin mushrooms from Jamaica to Canada. Technology Networks caught up with the company's chief scientific officer, Rob Roscow, to find out more.
The researchers found MDMA-assisted psychotherapy to have a particularly “impressive effect size” in reducing PTSD symptoms. But they say more studies will be needed before the drug can be recommended for clinical practice.
Regulation is incoming for the UK's CBD industry. But are companies clued up on the new requirements? Not always, say CBD analysts, and the confusing guidance may be partly to blame.
Explore the phytoremediation properties of hemp and why it has been used to clean up toxic waste sites where other types of remediation have failed.